Results 131 to 140 of about 14,363 (238)

Semi‐Physiological Population Pharmacokinetic Modeling of Oral and Intravenous Paracetamol to Quantify Presystemic Metabolism and Enterohepatic Recirculation

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Paracetamol (PCM) is extensively metabolized in the liver via glucuronidation, sulfation, and oxidation. Although oral and intravenous PCM are commonly used interchangeably, a comprehensive evaluation of PCM metabolism across both routes is lacking.
Cedric Lau, Charlotte van Kesteren, Robert M. Smeenk, Marieke M. Beex‐Oosterhuis, Birgit C. P. Koch, Lingtak‐Neander Chan, Yvonne S. Lin, Anne van Rongen, Catherijne A. J. Knibbe, Alwin D. R. Huitema, Hinke Huisman‐Siebinga   +10 more
wiley   +1 more source

Assessment and Benchmarking of Model Informed Approaches in Drug Development for Hemoglobinopathies: A Review of Scientific Advices From January 2000 to December 2024

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Despite the fact that modeling and simulation are now recognized as promising innovative methodologies, their use in the context of development of drugs for sickle cell disease and Thalassemia has not yet been reviewed. Considering the challenges of conducting clinical trials for hemoglobinopathies, our work aims at exploring the current ...
Grace Shalom Govere, Jean‐Michel Dogné, Flora Musuamba   +2 more
wiley   +1 more source

Population Pharmacokinetic–Pharmacodynamic Analysis of Zolpidem in Healthy Volunteers: Covariate Contributions to Variability in CNS Responses

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Population pharmacokinetic–pharmacodynamic (PK–PD) modeling was used to explore covariate effects on zolpidem PKs and PDs in 30 healthy Korean volunteers (15 males, 15 females) who received a single 10 mg dose. The dataset included 325 PK observations and 388 observations each for the digit symbol substitution test (DSST), choice reaction time
Hyun Chul Kim, Jung Sunwoo, Seonghae Yoon, In‐Jin Jang, Jae‐Yong Chung   +4 more
wiley   +1 more source

Physiologically Based Pharmacokinetic Modeling of Antibiotics in Children: Perspectives on Model-Informed Precision Dosing

Antibiotics
The appropriate use of antibiotics is crucial and involves selecting an optimal dosing regimen based on pharmacokinetic (PK) and pharmacodynamic (PD) indicators.
Ryota Tanaka, Kei Irie, Tomoyuki Mizuno
doaj   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Integrating B Cell Differentiation Model With Real‐World Data Informs Determinants for Antibody‐Secreting Cell Depletions in Systemic Sclerosis

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 3, March 2026.
ABSTRACT Systemic sclerosis (SSc) is a complex autoimmune disorder characterized by extensive fibrosis, vascular abnormalities, and immune dysregulation, affecting clinical outcomes such as skin thickness and pulmonary function with high mortality rates. B cells play a pivotal role in the pathogenesis of SSc. This study aimed to develop a systems model
Tomohisa Nakada, Ryuta Saito, Sho Ishigaki, Hiroshi Takei, Keiko Yoshimoto, Mitsuhiro Akiyama, Tsutomu Takeuchi, Yuko Kaneko, Fumihiko Miyoshi   +8 more
wiley   +1 more source

Global Sensitivity Analysis of a Physiologically-based Pharmacokinetic (PBPK) Model of Bromochloromethane [PDF]

, 2020
Sawyer, Colton
core   +1 more source

Monte Carlo Simulation in Environmental Risk Assessment--Science, Policy and Legal Issues [PDF]

, 1998
Dr. Poulter notes that agencies should anticipate judicial requirements for justification of Monte Carlo simulations and, meanwhile, should consider, e.g., whether their use will make risk assessment policy choices more opaque or ...
Poulter, Susan R.
core   +1 more source

Evaluation of the Effect of Food and Formulation on the Pharmacokinetics of the SHP2 Inhibitor Migoprotafib Within a Phase I Study in Cancer Patients

Clinical and Translational Science, Volume 19, Issue 3, March 2026.
ABSTRACT Migoprotafib is a potent and selective inhibitor of Src homology‐2 domain‐containing phosphatase 2 (SHP2) under investigation in Phase I (PhI) trials both as monotherapy and in combination with multiple therapies for patients with metastatic solid tumors.
Julia Suchomel, Christine M. Bowman, Po‐Chang Chiang, Mallika Dhawan, Jennifer Eng‐Wong, Paloma Hauser, Ryan Johnson, Ariel R. Muliadi, Swathi Pisupati, Vidya Ramakrishnan, Leonie Wagner, Sandhya V. Mandlekar   +11 more
wiley   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 4, April 2026.
wiley   +2 more sources